Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial by Windbichler, G H et al.
Ovarian cancer is one of the major causes of cancer death in
women and the leading cause among gynaecological malignan-
cies. The concurrent standard of treatment for these patients after
initial surgery consists of a platinum-based chemotherapy.
Recently, McGuire et al (1996) could demonstrate that inclusion of
paclitaxel into the first-line therapy resulted in improved overall
survival (OS). Although such advances in treatment have
improved outcome, survival of patients diagnosed with advanced
disease is still poor (Ozols et al, 1997). In the effort to find new
therapeutic modalities, we focused our interest on biologic modi-
fiers such as interferons (IFNs) because of their well defined
pleiotropic biological actions (Billiau, 1996). IFN-g, which is
produced by activated T-cells and natural killer (NK) cells exerts
antiproliferative effects on neoplastic cells including ovarian
cancer cells, as demonstrated by Saito et al (1986). It is essential
for tumour rejection in animal models (Malik et al, 1991; Dighe et
al, 1994) and leads to enhanced immunogenicity of tumour cells,
probably mainly by induction of cell surface antigens (Kaplan et
al, 1998).
Particularly, all types of IFNs augment MHC class I expression,
which has also been demonstrated for ovarian cancer cells, and
IFN-g, but not type I IFNs, induces a marked increase in MHC
class II antigens (Marth et al, 1996) and in adhesion molecules.
IFN-g is further known to up-regulate surface expression of CA
125 (Marth 1989), which also could modulate targetability for
corresponding antibodies or sensitized T-cells. Another mecha-
nism of inhibition of tumour cell proliferation might be the ability
of IFN-g to down-regulate the message and encoded protein of the
proto-oncogene HER-2/neu as demonstrated for ovarian cancer
cells by Marth et al (1990). Increased expression of this membrane
protein with structural homology to the epidermal growth factor
receptor possibly provides a selective advantage in proliferation
and has been found to be associated with poor prognosis and
cisplatin resistance (Hancock et al, 1991). In a previous study we
found that IFN-g decreased mRNA expression of HER-2/neu,
even in cisplatin-resistant cells, although it did not restore cisplatin
sensitivity (Marth et al, 1997).
Moreover, modulatory effects of IFN-g on cells of the immune
system include the stimulation of NK cells and macrophages. The
augmentation of cytotoxicity of macrophages was demonstrated
by Mannel and Falk (1983) under preclinical, and Allavena et al
(1990) under clinical, conditions.
Interleukin (IL)-12, the essential mediator of TH1 differentiation
in naive T-cells directly induces IFN-g gene transcription, which is
itself a major characteristic and effector molecule of the TH1
cytokine response. IFN-g, in turn, helps maintain a TH1 cytokine
profile and the associated cellular immune response by reciprocal
induction of IL-12, thus forming a positive feedback loop (Boehm
et al, 1997). Although these properties make IFN-g an attractive
potential anticancer agent, clinical studies for ovarian cancer have
been limited to only a few trials. Mostly, an intraperitoneal (i.p.)
route was chosen, because the disease mostly remains confined to
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progression and locally higher concentrations of the agent are
achievable by i.p. administration. While earlier trials with i.p. IFN-
g and limited numbers of patients yielded contradictory results
(D’Acquisto et al, 1988; Allavena et al, 1990; Colombo et al,
1992), recently Pujade-Lauraine et al (1996) reported an overall
response rate of 31% in a series of 108 patients with residual
disease at second-look laparotomy after cisplatin-based first-
line chemotherapy. Intraperitoneal IFN-g was administered twice
weekly in a dose of 20 ´ 106 IU m–2. Of 71 patients who were re-
evaluated surgically, women who were less than 60 years old and
had a residual tumour of less than 2 cm at initiation of IFN treat-
ment (n = 42) achieved an objective response rate of 54%.
Only a few trials for ovarian cancer have been conducted using
systemically applied IFN-g. Welander et al (1988) reported a high-
dose regimen (2 mg m–2 daily intravenously (i.v.)) to be active in
relapsing ovarian cancer with 4/14 patients responding. However,
preclinical studies found a dose of 0.1 mg effective in stimulating
immunological responses. Maluish et al (1988) demonstrated
monocyte and NK cell activation by subcutaneous (s.c.) or intra-
muscular (i.m.) application at this level. Kleinerman et al (1986)
tested the stimulation of monocyte-mediated cytotoxicity from
patients undergoing phase I trials with IFN-g. Treatment with a
dose of 1 mg m–2 i.m. did not produce anti-tumour activity, while
in the same patients cytotoxic monocyte function was restored
when the dose of IFN-g was reduced to 0.5 mg m–2. Aulitzky et al
(1987) used neopterin and b2-microglobulin as markers to monitor
the biological response to IFN-g in patients with renal cell
carcinoma. IFN-g in a dose range of 0.01–0.5 mg produced strong
dose-dependent up-regulations of both markers after the first injec-
tion. However, the neopterin response was down-regulated with
repeated injections at all dose levels. Markedly reduced b2-
microglobulin levels were seen with repeated application of 
0.5 mg IFN-g, the highest dose tested. Thus, although mono-
cyte–macrophage activation is well documented, higher doses and
repeated continuous applications may lead to immunosuppression
possibly by counter-regulatory effects.
In vitro data further demonstrated synergistic inhibition of
proliferation of ovarian cancer cells in treated simultaneously with
cisplatin and IFN-g (Nehmé et al, 1994).
With this background we initiated a randomized phase III trial to
evaluate the therapeutic potential of IFN-g in the first-line therapy
of ovarian cancer given together with a cisplatin-based
chemotherapy. A low-dose IFN-g scheme with 0.1 mg s.c. three
times a week on alternate weeks was chosen to circumvent a
possible immunosuppression by continuous application and high
doses. For ovarian cancer this is the first trial with IFN-g in the
first-line therapy and concomitantly to chemotherapy.
PATIENTS AND METHODS
Patients
This prospective randomized study was performed in 12 Austrian
gynaecological and medical centres between December 1991 and
March 1998 with enrolment of patients until March 1997. The
study protocol was approved by the Ethical Committee of the
University of Innsbruck Medical School as well as the respective
committees of the other participating centres. All patients gave
their written informed consent before enrolment.
Eligible patients had undergone primary surgical debulking of
histologically confirmed invasive epithelial ovarian cancer in
FIGO stages Ic–III. Patients in FIGO stage IV could be included if
this was due to malignant pleural effusion only. Additional eligi-
bility criteria were WHO performance status 0–2, adequate renal
function (creatinine clearance ³ 60 ml min–1), sufficient hepatic
function (bilirubin ≤ 1.5 mg dl–1), WBC count ³ 3g  l –1, platelet
count ³ 100 g l–1, and age less than 75 years. Moreover, patients
with concomitant severe cardiovascular disease, life expectancy of
less than 3 months, patients with a recent second malignancy or
history of thrombo-embolic disease were excluded. Patients were
enrolled up to 4 weeks after initial surgery, but before any other
treatment.
Randomization and treatment
Randomization was stratified by treatment centre and the amount
of residual tumour after surgery (< 2 cm vs ³ 2 cm). The random-
allocation lists for each treatment centre were computer-generated
at entry into the study. Patients were allocated to a treatment arm
by the study centre by means of fax transmission.
To avoid interobserver variability in tumour grading, all avail-
able slides were reviewed by one pathologist (EM-H).
Eligible patients were randomly assigned to receive either 
a standard chemotherapy regimen consisting of cisplatin and
cyclophosphamide (CP), given every 4 weeks or the same
chemotherapy regimen on the second of 28 days combined with
recombinant IFN-g 0.1 mg in a fixed dose administered s.c. on
days 1, 3, 5 and 15, 17, 19.
Patients in both treatment groups received i.v. cisplatin 100 mg
m–2 body-surface area parallel to cyclophosphamide 600 mg m–2.
Courses of CP or CP plus IFN-g were repeated every 4 weeks for a
total of six cycles unless disease progression or limiting toxicity
occurred or patients refused further treatment. In case of myelode-
pression with white cell counts of less than 3 g l–1 or platelet counts
of less than 100 g l–1, therapy could be delayed for a maximum of
3 weeks. If myelopoiesis did not regenerate during this time, treat-
ment was continued with cisplatin only. In the case of a nadir of
leucocytes < 1 g l–1 or platelets < 20 g l–1 the cyclophosphamide
dose was reduced by 25%.
IFN treatment
Human recombinant IFN-g (a donation of Bender, Vienna,
Austria) was administered s.c. in a fixed dose of 0.1 mg three
times weekly every other week (corresponding to 2 ´ 106 IU).
According to protocol interferon treatment was discontinued in
the event of grade 4 toxicities other than alopecia or myelosup-
pression and in the case of newly diagnosed thrombo-embolic
disease.
Premedication with paracetamol 1 g was allowed to ameliorate
IFN-induced fever or other flu-like symptoms.
Clinical assessments and response criteria
At baseline and after six courses of therapy a physical examination
was performed together with a blood count, serum CA 125 and
blood chemical measurements, chest radiography and computer-
ized tomography (CT) scan. In addition, blood counts and chem-
ical measurements were performed at the start of each cycle.
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operation after completion of therapy was not obligatory, and if
performed by the attending clinician, the result was not taken into
account for evaluation of response. Patients with residual disease
or tumour progression during therapy were considered evaluable
for response. A complete clinical response (CR) was defined as no
clinical evidence of disease after completion of therapy according
to the results of the gynaecological examination, CT scan and CA
125 serum levels. A partial response (PR) was taken to be tumour
regression ³ 50% and progressive disease (PD) tumour growth 
³ 25%. No change (NC) was defined as regression < 50% or
growth < 25%.
Salvage therapy was individualized according to the decision of
the attending clinician.
Statistical analysis
The primary end points were progression-free and overall
survival. Secondary end points were response and toxicity.
Progression-free (PFS) and overall survival (OS) were calcu-
lated using the method of Kaplan–Meier, comparisons of survival
distributions were made with the log-rank test, a = 0.05. Since the
stated aim of the study was to determine whether treatment with
IFN-g improved outcome, one-tailed P-values in univariate
analysis are reported. PFS was defined as the interval between the
initial surgery and last follow-up evaluation, diagnosis of progres-
sion or death from disease, whichever occurred first. OS was
calculated according to the date of last contact alive or death from
any cause. Calculation of the test power was based upon a 0.05
level one-tailed log-rank test for equality of survival curves.
Treatment group, size of residual tumour (none vs < 2 cm vs 
³ 2 cm), FIGO stage (Ic–IIc vs III–IV), histological type (serous,
mucinous, endometroid vs clear cell, undifferentiated), grading 
(I vs II vs III), ascites at initial surgery (none vs < 500 ml vs 
> 500 ml) and age were included as covariates in a Cox regression
analysis of PFS and OS. Comparisons of risk were based on the
Wald test. Two-tailed P-values are reported, because the level of
significance was equal for all covariates, which were tested with
regard to their influence on survival either way. Differences in
proportions of toxic effects and distributions of baseline character-
istics and response groups were analysed by the two-tailed c2 or
Fisher’s exact test when appropriate. The Wilcoxon’s rank sum
test was utilized to compare medians.
Data processing was performed by means of SPSS for Windows
(SPSS Inc., Chicago, IL, USA).
RESULTS
Patients
Between December 1991 and April 1997, 148 women were
enrolled in the study and randomly assigned to receive either IFN-
g with cyclophosphamide (CP) or CP alone. Randomization was
terminated before the originally planned number of 200 patients
was reached, because meanwhile the standard of care had changed
to a platinum- and taxane-based therapy. A total of 15 patients
were ineligible (ten in the group with IFN and five in the CP-only
group) for the following reasons: borderline tumour (in three
cases), histology other than epithelial ovarian cancer (in two),
FIGO stage that did not meet the inclusion criteria (in seven),
insufficient renal function (in one) and consent withdrawn and no
more contact after surgery (in two). Table 1 shows the characteris-
tics of the remaining 133 eligible patients. There were no signifi-
cant differences between the study groups with respect to
important prognostic parameters, as shown in Table 1. Three
major protocol violations occurred among the 68 eligible patients
of the CP-only group: One patient received cisplatin combined
with paclitaxel instead of cyclophosphamide and in two cases
cisplatin was substituted with carboplatin. In the IFN group with
65 patients carboplatin instead of cisplatin was used in two
patients. According to the intent-to-treat principle all 133 eligible
patients were included in the efficacy analysis.
Dose intensity (Table 2)
Of 61 eligible patients in the CP-only group, who did not discon-
tinue therapy due to progression of disease, 64% completed six
cycles as scheduled. On the other hand, 53% of 59 responding
patients in the IFN group received six cycles of the combined
treatment. In the IFN group only cycles with full IFN and
cisplatin/cyclophosphamide treatment were counted. Although in
the IFN group a lower percentage of patients completed treatment
as scheduled, the difference was not statistically significant (P =
0.75). In addition, the dose of cisplatin was reduced in 18% of
sixth CP plus IFN-g cycles and in 10% of such cycles in the
control group (n.s.).
Response (Table 3)
Response was assessed in 81 patients with residual disease after
initial surgery or disease progression under first-line therapy.
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Table 1 Patient characteristics
Treatment
Characteristics CP plus IFN-g CP
(n = 65) (n = 68)
n % n %
Age (median, range) 56, 21–75 56, 22–75
FIGO stage
Ic 7 11 11 16
II 9 14 6 9
III 48 74 47 69
IV (malignant pleural effusion only) 1 1 4 6
Residual tumour
No gross residual disease after surgery 27 41 25 37
Small residual disease (< 2 cm) 22 34 27 40
Bulky residual disease (³ 2 cm) 16 25 16 23
Histological type
Serous 45 70 45 66
Mucinous 9 14 14 21
Endometrioid 3 5 6 9
Clear cell 2 3 2 3
Undifferentiated 5 8 1 1
Grading
I1 1 1 8 1 0 1 5
II 30 49 30 45
III 20 33 27 40
Unknown 4 1
Ascites
None 24 38 31 48
< 500 ml 17 27 14 22
> 500 ml 22 35 19 30
Unknown 2 4Clinical criteria were used as described in Patients and Methods.
Of the IFN-g treatment arm 38 patients were evaluable; 26 (68%)
reached clinical complete response (CR), in contrast to 24 of 43
(56%) in the control group (Table 3). Partial response (PR) was
achieved by 11% versus 21%, and disease progression was found
in 21% versus 23% resulting in overall response rates of 79% and
77% (n.s.). No significant differences were found, but 50% of
IFN-treated patients with bulky residual tumour achieved CR
(eight of 16) compared to 19% in the control arm (three of 16). The
figures for PR are 19% and 31%, respectively, resulting in overall
response rates of 69% versus 50% (n.s.).
Toxicity (Table 4)
As shown in Table 4a, haematological toxicity was found to be
equal between treatment cycles with CP alone and those combined
with IFN-g. Also, no enhanced nephro- or hepatotoxicity was
observed in the treatment arm. Severe emesis (WHO grades 3 and
4) occurred in equal proportions of treatment cycles in both
groups. As demonstrated in Table 4b, neuropathy was also not
more frequent in IFN-g-treated patients.
Most patients with IFN-g therapy suffered from a flu-like
syndrome, which consisted mostly of cephalea, fatigue, chills and
fever. Characteristically, symptoms set on shortly after IFN injec-
tion and lasted for several hours. There was no mitigation in the
course of repeated applications.
Thrombo-embolic complications occurred with equal frequen-
cies in the IFN-g and control group (6% and 5%).
Additional adverse events not listed in Table 4 in the IFN treat-
ment group and possibly associated with treatment included a newly
diagnosed diabetes mellitus type II, a septicaemia caused by
Escherichia coli and an AV block grade II–III, the latter two leading
to discontinuation of IFN treatment. One patient experienced a
severe depression that abated after discontinuation of IFN-g.
Survival
Median follow-up was 29 and 24 months for overall (OS) and
progression-free survival (PFS) respectively. Of 65 patients
randomized to receive IFN-g, 27 had disease progression as
compared with 43 of 68 control patients. Median times to progres-
sion were 48 and 17 months, respectively, corresponding to rates
of 51 versus 38% of 3-year PFS (Figure 1, P = 0.031, one-tailed).
The two groups did not differ significantly in OS: 18 patients
who received IFN-g died and 21 deaths occurred in the control
group. Median survival has not yet been reached, neither in the
IFN-g nor in the control group and 3-year OS is 74 and 58%
(Figure 2, P = 0.23, one-sided). However, with a sample size of 65
and 68 patients in each group, a 0.05 level one-sided log-rank test
for equality of survival curves will only have a 65% power to
detect a difference between the above stated proportions after 3
years observation time (b = 0.35). If the originally planned sample
size of 200 had been reached (100 patients per group), the test
power would have been 81%.
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Table 2 Dose intensity. Percentage of eligible patients receiving
cisplatin/cyclophosphamide plus IFN-g or cisplatin/cyclophosphamide
according to treatment schedule during each course and percentage of
cisplatin courses with full initial dose
Treatment Patients receiving assigned Cisplatin dose
course therapy
IFN group Control IFN group Control
% of patients % of cycles with initial dose
1 97 97 100 100
2 85 89 95 100
38 0 8 2 8 9 9 8
47 3 7 7 8 6 9 8
56 4 7 5 8 6 9 6
65 3 6 4 8 2 9 0
Table 3 Clinical response of 81 evaluable patients with residual disease
after primary surgery or patients with disease progression under first-line
therapy.
n = 81 Responsea CP plus IFN-g CP only P
n = 38 n = 43
n % n %
All patients CR 26 68 24 56
evaluable for PR 4 11 9 21 0.38
response PD 8 21 10 23
Residual tumour n = 22 n = 27
< 2 cm CR 18 82 21 78
PR 1 4 4 15 0.41
PD 3 14 2 7
³ 2c m n = 16 n = 16
CR 8 50 3 19
PR 3 19 5 31 0.17
PD 5 31 8 50
aCR, complete response; PR, partial response; PD, progressive disease.
Table 4a. Frequency of toxic effects according to treatment cycles
WHO grade 1/2 3/4
Treatment arm + IFN-g CP +IFN-g CP
(% of treatment cycles)
Anaemia 21 24 0 0
Neutropenia 25 20 1 0
Thrombocytopenia 2 1 0 1
Creatinine 1 1 0 0
Bilirubin 1 1 0 0
SGOT 3 3 0 0
Emesis 76 73 14 14
Alopecia 48 48 10 14
Table 4b Frequency of toxic effects according to patients
WHO-grade 1/2 3/4
Treatment arm + IFN-g CP +IFN-g CP
(% of patients)
Neurotoxicity 30 36 4 2
including ototoxicity
Viral infection 8 2 0 2
Fever 74 9 3 2
Flu-like syndromea 6 623 0
Thrombosisb 65
aSymptoms including cephalea, fatigue, chills, myalgia. bWHO grading not
relevant.Multivariate analysis revealed that size of residual tumour and
age were independent factors influencing OS and PFS when these
parameters were included as covariates together with FIGO stage,
ascites, histological type, grading and treatment arm. By contrast
to overall survival, analysis of progression-free survival showed
IFN-g treatment to also be significantly associated with outcome
with a reduction of the relative risk to 0.48 (95% confidence
interval (CI) 0.28–0.82) as compared to the control group.
Table 5 shows the relative risk (RR) and P-values (two-tailed).
To further analyse interferon-mediated effects subgroups of
patients with small and large volume residual disease (< 2 cm and
> 2 cm) have been evaluated (Figure 3). Three-year PFS was 53%
(CP only) and 66% (CP plus IFN-g) for patients with small volume
residual disease (n.s.) and none versus 22% in the group with 
> 2 cm residual disease (P = 0.01). For OS, the corresponding
figures are 65–80% and 36–56% (n.s.).
DISCUSSION
Although IFN-g has been demonstrated to be effective in the
second-line therapy of epithelial ovarian cancer, to our knowledge
no trials have so far tested this substance in the first-line treatment
or in combination with chemotherapy. Our randomized prospective
study included 148 patients (133 evaluable) with mostly advanced
disease (75% FIGO stage III or IV). After initial debulking surgery
all women were treated with the same standard chemotherapy
regimen, which at the time of initiation of the study was a combina-
tion of cisplatin and cyclophosphamide, while patients allocated to
the study group concomitantly received low-dose IFN-g (three
times a week in alternate weeks as described in Patients and
Methods) in systemic application. The initial plan to include 200
patients had to be abandoned because the standard of care changed
from chemotherapy with cisplatin and cyclophosphamide to a
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Figure 1 Progression-free survival by treatment arm Figure 2 Overall survival by treatment arm
Figure 3 Progression-free survival in patients with small residual tumour 
(< 2 cm) and bulky residual tumour (> 2 cm) by treatment arm
Table 5 Cox regression analysis of survival including treatment group,
amount of residual tumour, age, FIGO stage, ascites, histological type and
grading as covariates.
Factors associated RR 95% Clb P a
with survival
Progression-free survival
IFN-g treatment No 1.0 0.007
Yes 0.48 0.28–0.82
Size of residual tumour None 1.0 0.0000
< 2 cm 3.5 1.7–7.4
³ 2 cm 7.7 3.7–16.0
Age < 55 years 1.0 0.05
³ 55 years 1.7 1.0–2.9
Overall survival
Size of residual tumour None 1.0 0.0007
< 2 cm 8.3 2.4–28.2
³ 2 cm 11.0 3.2–37.8
Age < 55 years 1.0 0.001
³ 55 years 2.5 1.2–5.1
RR, relative risk; CI, confidence interval. aAll P-values are two-sided.IFN-g in the first-line treatment of ovarian cancer 1143
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platinum plus taxane combination. The power of the trial to detect a
15% difference in survival after 3 years would have been 81%
(one-tailed log-rank test) for 100 patients per group and is 65% for
the achieved sample size of 65 per group.
We found that IFN-g treatment significantly improved PFS from
a median of 17 months in the control group to 48 months, corre-
sponding to rates of 38% and 51% for 3 year PFS (P = 0.031, one-
tailed log-rank test). This result was substantiated by the fact that
in multivariate analysis increased PFS was also significantly
associated with IFN-g treatment (Cox regression, P = 0.007, two-
tailed). The RR compared with the control group (RR = 1) was
reduced to 0.48 (CI 0.28–0.82). For overall survival, neither
univariate nor multivariate analyses showed a significant benefit,
although 3-year OS was improved from 58% to 74% (median not
yet reached).
Toxicity was substantially the same in both treatment groups,
except for the typical side-effects known to be associated with IFN
therapy. These consisted mainly of a flu-like syndrome with fever,
headache, fatigue and myalgia, and characteristically set on some
hours after IFN-g administration. The symptoms were observed in
most patients receiving IFN-g but were generally mild (Table
4a/b). Although more patients in the study group discontinued the
scheduled therapy before completing six cycles, this difference
was not significant.
Response was evaluated for patients with residual tumour and
those who progressed under first-line therapy (Table 3). A CR was
achieved in 68% treated with IFN-g and 56% of controls.
Interestingly, 50% of patients with bulky residual disease (8/16)
achieved a CR versus 19% in the control group (3/16). In the
subset with small residual tumour CR were observed in 82% and
78%. Possibly due to small numbers, none of these was statisti-
cally significant. In ovarian cancer IFN-g has been tested to date
solely in the second-line therapy and mostly in i.p. application in
the case of peritoneal carcinomatosis. In a phase II trial with 108
patients, Pujade-Lauraine et al (1996) reported a response rate of
43% for patients with small volume residual disease (27/63). In
contrast, only four of 35 (11%) patients with tumours > 2 cm
responded. These results are supported by a smaller study by
Colombo et al (1992) of eight patients with small-volume residual
disease (< 1 cm) with three of eight patients responding. Similarly,
in a study by Berek et al (1985) i.p. IFN-a showed efficacy only in
small-volume i.p. disease, while no response was seen in tumours
> 2 cm. This is in accordance with a general observation, that
immunotherapeutic agents are more successful in patients with
small tumour burden.
In contrast, in the present study, there was equal efficacy in
patients with small and large tumour burden, although subset
analysis is limited because of small numbers of patients. As stated
above, response rates were improved also in patients with bulky
disease. Improvement in survival, especially PFS, was also 
seen in both groups to a similar extent. The combination with
chemotherapy might augment the response to IFN in accordance
with the results of Weisenthal et al (1991), who found enhanced
tumour-specific cytotoxic effects by IFN-g in tumour specimens,
that were obtained from patients previously treated with and
responding to chemotherapy, as compared to not treated or not
responding tumours. Possibly, the massive release and processing
of tumour antigens primes the immune system to respond to
exogenous activating signals with more potent anti-tumour effects.
Our results therefore warrant further testing of IFN-g in the
therapy of ovarian cancer. IFN-g combined with the present stan-
dard chemotherapy of a platinum and a taxane compound particu-
larly deserves to be evaluated.
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